#AI drug discovery

63 stories · 6 in 7 days · 39 in 30 days
Stories, products and papers tagged "AI drug discovery", newest first.
Nov 13
Chinese contentOrakl Oncology 融资 3400 万美元,用虚拟癌症患者预测临床试验结果

这家法国公司把肿瘤类器官养在实验室里当"虚拟病人",再用模型预测药厂临床试验成败,号称 90% 准确率。跟纯靠历史基因组数据的方法比,多了活体实验验证这层。关注 AI 制药、临床前筛选的从业者可以看看。

HIT Consultant@Fred PennicSource
Nov 12
Chinese contentPhaSER Biomedical获盖茨基金会270万美元资助,推进8HUM模型与HERALD AI

药企做临床前毒性筛选的老办法是拿小鼠凑合,人代谢和小鼠代谢差太多,漏掉的毒性到人体试验才暴露。这家苏格兰公司用带人类代谢酶基因的转基因小鼠加HERALD AI来补这个坑,盖茨基金会给了270万美元。做药物研发或关注AI制药的人可以看看。

HIT Consultant@Jasmine PennicSource
Chinese content谷歌 DeepMind 发布 AlphaGenome 2:深入单细胞层面预测基因变异影响

DeepMind 把基因组预测从组织级别推进到了单细胞级别,致病变异识别率从 16% 提到 30%,还首次支持 DNA 甲基化预测。做遗传学、药物研究的科研人员可以直接用 API 免费跑,不用自己微调模型就能分析新细胞类型。

IT之家Source
IndustryBuildersMulti-source00:52
Chinese contentDario Amodei 预测癌症、阿尔茨海默病等疾病十年内或被攻克

Anthropic 的 CEO 放话十年内攻克癌症和阿尔茨海默病,正好卡在 IPO 节点前,动机值得琢磨。AI 制药确实在提速,但十年说法业内争议不小。关心 AI 医疗落地和 Anthropic 动向的人可以看看各方怎么看。

Event
kimmonismus@kimmonismusSource
Nov 11
ProductsBuildersSelected23:27
Google DeepMind releases AlphaGenome 2 for cell-specific disease research

Cell-specific variant interpretation is a bottleneck in translating genome sequencing into clinical insight, and AlphaGenome 2 targets exactly that gap. Genomics labs, computational biologists, and biotech teams evaluating disease-causing mutations can use it to prioritise variants by affected tissue. Compared with AlphaFold, which resolved protein structure, this model moves DeepMind's tooling upstream into gene regulation, a space where competitors like Enformer and Evotec partnerships have been active.

Official accountGoogle DeepMind@GoogleDeepMindSource
Nov 6
Nov 5
Nov 3
Nov 2
Oct 30
Oct 29
Oct 28
Oct 27
Oct 26
Oct 25
Oct 24
Oct 23
Oct 22
Oct 21
Oct 20
Oct 16
Oct 15
How-toBuildersSelected05:41
LeashBio Turns Wet-Lab Data into Replayable RL Environments

The Kaggle result — nobody beat chance on an unseen library — is a blunt warning that chemistry benchmarks reward memorization, and protein-mutation probes make that visible. The replayable-environment framing gives ML researchers a concrete template for grounded, agentic experimentation beyond text and code. Teams building benchmark suites or applying AI in pharma should study how LeashBio got from DEL hit to mouse studies in six months.

Event
Latent.Space@latentspacepodSource
Oct 13